431 related articles for article (PubMed ID: 16843668)
1. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
[TBL] [Abstract][Full Text] [Related]
2. New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents.
Ismail MM; Amin KM; Noaman E; Soliman DH; Ammar YA
Eur J Med Chem; 2010 Jul; 45(7):2733-8. PubMed ID: 20236735
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
[TBL] [Abstract][Full Text] [Related]
4. Selective hypoxia-cytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N1,N4-dioxide derivatives.
Vieites M; Noblía P; Torre MH; Cerecetto H; Laura Lavaggi M; Costa-Filho AJ; Azqueta A; de Cerain AL; Monge A; Parajón-Costa B; González M; Gambino D
J Inorg Biochem; 2006 Aug; 100(8):1358-67. PubMed ID: 16698084
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivatives.
Zarranz B; Jaso A; Aldana I; Monge A
Bioorg Med Chem; 2004 Jul; 12(13):3711-21. PubMed ID: 15186857
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.
Urquiola C; Vieites M; Torre MH; Cabrera M; Lavaggi ML; Cerecetto H; González M; Cerain AL; Monge A; Smircich P; Garat B; Gambino D
Bioorg Med Chem; 2009 Feb; 17(4):1623-9. PubMed ID: 19162490
[TBL] [Abstract][Full Text] [Related]
7. Novel N-oxide of naphthalimides as prodrug leads against hypoxic solid tumor: synthesis and biological evaluation.
Yin H; Xu Y; Qian X; Li Y; Liu J
Bioorg Med Chem Lett; 2007 Apr; 17(8):2166-70. PubMed ID: 17331719
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues.
Solano B; Junnotula V; Marín A; Villar R; Burguete A; Vicente E; Pérez-Silanes S; Aldana I; Monge A; Dutta S; Sarkar U; Gates KS
J Med Chem; 2007 Nov; 50(22):5485-92. PubMed ID: 17910426
[TBL] [Abstract][Full Text] [Related]
9. Hypoxic cells in tumors as a target for cancer therapy.
Gali-Muhtasib HU; Diab-Assef M; Haddadin MJ
J Med Liban; 2002; 50(4):175-9. PubMed ID: 15298478
[TBL] [Abstract][Full Text] [Related]
10. Novel N-oxides as bioreductive drugs.
Naylor MA
Oncol Res; 1994; 6(10-11):483-91. PubMed ID: 7620216
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
12. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
Lee HH; Wilson WR; Denny WA
Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides.
Grande F; Aiello F; Grazia OD; Brizzi A; Garofalo A; Neamati N
Bioorg Med Chem; 2007 Jan; 15(1):288-94. PubMed ID: 17085054
[TBL] [Abstract][Full Text] [Related]
14. Selective activity against Mycobacteriumtuberculosis of new quinoxaline 1,4-di-N-oxides.
Vicente E; Pérez-Silanes S; Lima LM; Ancizu S; Burguete A; Solano B; Villar R; Aldana I; Monge A
Bioorg Med Chem; 2009 Jan; 17(1):385-9. PubMed ID: 19058970
[TBL] [Abstract][Full Text] [Related]
15. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
[TBL] [Abstract][Full Text] [Related]
16. Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs.
Gali-Muhtasib HU; Haddadin MJ; Rahhal DN; Younes IH
Oncol Rep; 2001; 8(3):679-84. PubMed ID: 11295102
[TBL] [Abstract][Full Text] [Related]
17. 1, 2, 4-Triazine N-oxide derivatives: studies as potential hypoxic cytotoxins. Part II.
Cerecetto H; González M; Onetto S; Saenz P; Ezpeleta O; De Ceráin AL; Monge A
Arch Pharm (Weinheim); 2004 May; 337(5):247-58. PubMed ID: 15095418
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of new symmetrical derivatives as cytotoxic agents and apoptosis inducers.
Sanmartín C; Echeverría M; Mendívil B; Cordeu L; Cubedo E; García-Foncillas J; Font M; Palop JA
Bioorg Med Chem; 2005 Mar; 13(6):2031-44. PubMed ID: 15727857
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro-anticancer and antimicrobial evaluation of some novel quinoxalines derived from 3-phenylquinoxaline-2(1H)-thione.
El-Hawash SA; Wahab AE
Arch Pharm (Weinheim); 2006 Aug; 339(8):437-47. PubMed ID: 16881038
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. 2.
Monge A; Martínez-Crespo FJ; López de Ceráin A; Palop JA; Narro S; Senador V; Marín A; Sainz Y; González M; Hamilton E
J Med Chem; 1995 Oct; 38(22):4488-94. PubMed ID: 7473576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
